




Name	Dave Singh	
Country	UK	
Organization	University of Manchester	
Current Position	Professor of Clinical Pharmacology & Respiratory Medicine	

Educational Background

1979 – 1986 Colchester Royal Grammar School, Essex
 1986 – 1989 Queens College, Cambridge University BA (Hons) Medical Sciences 2:1
 1989 – 1991 Addenbrookes Medical School, Cambridge University MB, B.Chir.
 General Medical Council Registration 3612309

Professional Experiences

Current appointment (since 2011)

Professor of Clinical Pharmacology & Respiratory Medicine, Division of Infection, Immunity & Inflammation, Respiratory research group, University of Manchester, Manchester, UK. Honorary Consultant Respiratory Physician (Manchester University NHS Foundation Trust) & Medical Director at Medicines Evaluation Unit (Manchester University NHS Foundation Trust).

2003 – 2011 Reader/Senior Lecturer in Clinical Pharmacology & Respiratory Medicine, University of Manchester

1996 – 2003 Registrar and Senior Registrar Chest Medicine & Clinical Pharmacology; North West Lung Centre, South Manchester University Hospitals Trust; Department of Pharmacology and Therapeutics, Liverpool University; Clinical Pharmacology, AstraZeneca Pharmaceuticals, Alderley Edge

Professional Organizations

FBPhS (Fellow of the British Pharmacology Society; 2019)

FERS (Fellow of the European Respiratory Society; 2019)

Member of ATS and BTS



Main Scientific Publications

1. Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Mannent LP, Patel N, Staudinger HW, Yancopoulos GD, Mortensen ER, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM; BOREAS Investigators. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. *N Engl J Med.* 2023;389:205-214.
2. Brightling CE, Nair P, Cousins DJ, Louis R, Singh D. Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial. *N Engl J Med.* 2021;385:1669-1679
3. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P; ETHOS Investigators. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. *N Engl J Med.* 2020;383:35-48.
4. Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciruba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Benralizumab for the Prevention of COPD Exacerbations. *N Engl J Med.* 2019;381:1023-1034
5. Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. *Lancet.* 2019;394:1737-1749
6. Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. *Lancet Respir Med.* 2019;7:745-756
7. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. *N Engl J Med.* 2018;378:1671-1680.
8. Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet.* 2018;391:1076-1084
9. Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. *Lancet.* 2017;13;389:1919-1929.
10. Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β 2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. *Lancet.* 2016;388:963-73